Joshua Zeidner/ X ; Daniel Peters/ X
Jul 13, 2026, 10:49
Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
Joshua Zeidner, Professor of Medicine at The University of North Carolina at Chapel Hill, shared Daniel Peters‘s post on X, adding:
“True privilege to be part of the MD Education AML ALL US Focus 2026 meeting!
Always great to highlight the incredible advances of menin inhibitors and excited to discuss our upcoming RAVEN.
Study for newly diagnosed younger/fit KMT2Ar AML.”
Daniel Peters, Assistant Professor at Medical College of Georgia at Augusta University and Member of the Georgia Cancer Center, shared a post on X:
“One of the many great talks at MD Education AML-ALL focus group.
Joshua Zeidner at UNC Lineberger showing continued, impressive results of Menin-I in NPM1 and KMT2Ar AML and emphasis on frontline combos.
Tip of the iceberg!”
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026
-
Jul 13, 2026, 09:46Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
-
Jul 13, 2026, 09:42Cancer-Associated Arterial Thromboembolism: Redefining the Thrombotic Burden in Oncology
-
Jul 13, 2026, 05:59Connecting and Collaborating at ISTH 2026 – NNHF
-
Jul 13, 2026, 05:58Lara Monica: Back at ISTH – Looking Forward to Science and Reconnections!
-
Jul 13, 2026, 05:57Barbara Adams Krolak: Exciting Updates From the ISTH 2026 Regulatory Session
-
Jul 13, 2026, 05:57Alberto Maino: ISTH 2026 Has Just Begun